Dual PI3K/mTOR inhibition has been shown to be effective in MLL-rearranged AML cell lines.42 In our study, both FLT3 inhibitor-sensitive and resistant human AML cell lines responded to the potent PI3K/mTOR inhibitor gedatolisib.35 This is not unexpected because patients carrying FLT3-ITD display upregulation of the PI3K/mTOR signaling pathway. The gene discussed is MTOR; the disease is acute myeloid leukemia.